Rapporto sull’analisi delle dimensioni del mercato e delle quote dei biomarcatori del cancro | Previsioni 2031

  • Report Code : TIPBT00002663
  • Category : Biotechnology
  • Status : Upcoming
  • No. of Pages : 193
Buy Now

Il mercato dei biomarcatori del cancro è stato valutato a 18.436,36 milioni di dollari nel 2022 ed è probabile che raggiunga gli Stati Uniti $ 34.857,12 milioni entro il 2028 si stima che crescerà a un CAGR dell'11,1% nel periodo 2022-2028

Il biomarcatore, una molecola biologica, si trova nel sangue, nei tessuti o in altri fluidi corporei ed è un segno di un processo standard o anormale. Un biomarcatore viene utilizzato per vedere quanto bene il corpo risponde a un trattamento per una malattia o condizione.

Approfondimenti di mercato

Il lancio di nuovi prodotti e le approvazioni della FDA insieme al progresso tecnologico stimolano la crescita del mercato

Gli operatori del mercato stanno producendo un'ampia gamma di biomarcatori del cancro che offrono i massimi vantaggi e la diagnosi precoce. Nell'aprile 2021, Amgen ha lanciato Biomarker Assist, un programma per aiutare un numero maggiore di pazienti con carcinoma polmonare non a piccole cellule (NSCLC) metastatico (stadio IV) ad accedere ai test dei biomarcatori. Il test dei biomarcatori al momento della diagnosi è un primo passo fondamentale per indirizzare i pazienti al trattamento giusto. Attraverso Biomarker Assist, i pazienti idonei possono risparmiare sui test dei biomarcatori.

Inoltre, nel marzo 2022, Vela Diagnostics ha lanciato nuovi pannelli mirati (60 geni) e completi (525 geni) basati sul sequenziamento di prossima generazione (NGS) per rilevare biomarcatori tumorali di RNA e DNA da campioni di tessuto fissati in formalina e inclusi in paraffina (FFPE). I nuovi pannelli genetici del cancro pan includono il pannello mirato OncoKey SL 60 Plus e il pannello completo OncoKey SL 525 Plus.

Inoltre, nel dicembre 2021, BioGenex ha lanciato tre nuovi anticorpi immunoistochimici primari (IHC), tra cui CD8A, CD163 e CD56 per la diagnosi del cancro.

Inoltre, i recenti progressi nelle immunoterapie contro il cancro sono emersi in risposte cliniche di lunga durata nei pazienti. Le immunoterapie contro il cancro stanno rapidamente sostituendo gli standard di trattamento tradizionali e ampliando il panorama terapeutico per i pazienti affetti da cancro. I ricercatori si concentrano sulla ricerca di molecole nel sangue che possono segnalare la comparsa di tumori. Per la diagnosi del cancro dell'ovaio e della prostata, l'antigene tumorale (CA)125 e l'antigene prostatico specifico (PSA) vengono utilizzati insieme ad altri test.

Inoltre, i progressi nelle tecnologie omiche ad alto rendimento, tra cui genomica, proteomica, trascrittomica e metabolomica, hanno accelerato il ritmo della scoperta dei biomarcatori. Recentemente è stato adottato il concetto di identificare il DNA tumorale circolante attraverso una biopsia liquida è passato alla realtà clinica. La Society for Immunotherapy of Cancer (SITC) ha riunito nuovamente i biomarcatori per una task force immunitaria per esaminare le tecnologie all’avanguardia, identificare gli attuali ostacoli e formulare raccomandazioni per il settore. Pertanto, il recente progresso tecnologico ha abilitato molti potenziali biomarcatori e si è rinnovato nello sviluppo di nuovi biomarcatori e ha guidato la crescita del mercato dei biomarcatori del cancro

< strong>Approfondimenti strategici

Approfondimenti di mercato - Opportunità

Mercati emergenti nei paesi in via di sviluppo fornire opportunità lucrative per il mercato durante il periodo di previsione

Emergente mercati come l’Asia Pacifico stanno creando ampie opportunità per importanti operatori del mercato di espandere la propria attività. La maggior parte dei principali attori si concentra sui paesi emergenti come India, Cina e altri a causa del gran numero di malati di cancro e della crescita del turismo medico nei paesi in via di sviluppo. La maggior parte dei paesi emergenti sono il luogo preferito per il turismo medico.

Come da secondo l'Australian Institute of Health and Welfare, nel 2021 vengono diagnosticati 151.000 nuovi casi di cancro. Inoltre, secondo il Malaysia Healthcare Travel Council, nel 2020, più di 2 milioni di persone hanno visitato la Malesia per scopi sanitari, raddoppiando le entrate del turismo medico a circa 680 milioni. Il basso costo degli interventi chirurgici e le tecnologie avanzate con tempi di attesa inferiori per le procedure nella regione probabilmente aumenteranno la domanda di biomarcatori del cancro.

Pertanto, si prevede che la crescita del turismo medico nei paesi emergenti e l'aumento della prevalenza del cancro nell'Asia del Pacifico forniranno significative opportunità di crescita agli operatori che operano nel mercato dei biomarcatori del cancro durante il periodo di previsione.< /span>

Approfondimenti basati sul tipo di biomarcatore

Il mercato dei biomarcatori del cancro, in base al tipo di biomarcatore, è segmentato in biomarcatori genetici, proteine biomarcatori e altri. Il segmento dei biomarcatori proteici ha detenuto la quota maggiore del mercato nel 2022 e si prevede che registrerà il tasso di crescita più elevato durante il periodo di previsione.

Mercato dei biomarcatori del cancro, per tipo di biomarcatore – 2022 e 2028

Mercato dei biomarcatori del cancro, per tipo di biomarcatore - 2022 e 2028QIAGEN
  • bioMérieux Inc
  • Creative Diagnostics Hologic Inc
  • Myriad Genetic Inc
  • Quest Diagnostics
  • Report Coverage
    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered
    Segment Covered

    This text is related
    to segments covered.

    Regional Scope
    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope
    Country Scope

    This text is related
    to country scope.

    Frequently Asked Questions


    What are cancer biomarkers?

    National Cancer Institute defined biomarker as a biological molecule found in blood, or tissues or other body fluids that is a sign of a standard or abnormal process. A biomarker is employed to ascertain however well the body responds to a treatment for a malady or condition. Cancer biomarkers area unit the molecules that aid within the examination similarly because the treatment of various kinds of cancer. These molecules are often evaluated by aggregation samples like stool, neoplasm tissue, blood, urine, or alternative tissues or bodily fluids.

    What are the drivers for the cancer biomarkers market growth?

    The key factors that are driving growth of the market are growing cancer prevalence across the globe, new product launches and FDA approvals, and technological advancements.

    What are the restraining factors for the cancer biomarkers market across the globe?

    Unfavorable regulatory and reimbursement scenario is the major factor hindering the market growth.

    Which segment is growing at the highest CAGR in the Cancer biomarkers market?

    Based on biomarker types, the protein biomarker segment held largest share of the market and protein biomarker segment is projected to register the highest CAGR during the forecast period.

    What would be forecast period in the market report?

    The cancer biomarkers report contains forecast of 2019 to 2027.

    The List of Companies

    1. Bio-Rad Laboratories, Inc.
    2. Thermo Fisher Scientific, Inc.
    3. F. Hoffmann-La Roche Ltd.
    4. QIAGEN N.V.
    5. Illumina, Inc.
    6. Myriad Genetics, Inc.
    7. Hologic Inc.
    8. Quest Diagnostics Incorporated
    9. bioMérieux SA
    10. Creative Diagnostics

    The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

    1. Data Collection and Secondary Research:

    As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

    Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

    1. Primary Research:

    The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

    For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

    A typical research interview fulfils the following functions:

    • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
    • Validates and strengthens in-house secondary research findings
    • Develops the analysis team’s expertise and market understanding

    Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

    • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
    • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

    Below is the breakup of our primary respondents by company, designation, and region:

    Research Methodology

    Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

    1. Data Analysis:

    Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

    • Macro-Economic Factor Analysis:

    We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

    • Country Level Data:

    Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

    • Company Profile:

    The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

    • Developing Base Number:

    Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

    1. Data Triangulation and Final Review:

    The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

    We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

    We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Related Reports